|
시장보고서
상품코드
2008026
ANCA 혈관염 치료제 시장 : 유형별, 약제 유형별, 유통 채널별, 지역별ANCA Vasculitis Drug Market, By Type, By Drug Type, By Distribution Channel, By Geography |
||||||
ANCA 혈관염 치료제 시장은 2026년에 5억 7,490만 달러로 추정되고 있으며, 2033년까지 8억 3,630만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.5%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 5억 7,490만 달러 |
| 실적 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 5.50% | 2033년 시장 규모 예측 : | 8억 3,630만 달러 |
항호중구 세포질 자가항체(ANCA) 관련 혈관염(AAV)은 미세혈관의 염증 및 손상을 특징으로 하는 자가면역질환군입니다. 호중구에 결합하여 이를 과도하게 활성화시키는 ANCA라는 자가 반응성 항체가 이 염증의 원인이 되고 있습니다. 이러한 면역체계의 기능 장애는 유전적 요인이나 환경적 요인에 의해 발생합니다. ANCA 혈관염은 영향을 받는 장기나 신체 부위에 따라 다양한 증상을 유발할 수 있습니다. 예를 들어 피부의 혈관이 손상되면 발진이 발생할 수 있습니다. 신장 혈관에 문제가 생기면 혈액과 단백질이 소변으로 누출되어 신장 손상을 유발할 수 있습니다. ANCA 혈관염에는 현미경적 다발성 혈관염(MPA), 육아종성 다발성 혈관염(GPA), 호산구성 육아종성 다발성 혈관염(EGPA)의 세 가지 주요 유형이 있습니다. 현재 이 질환을 근본적으로 치료할 수 있는 방법은 없으며, 증상을 관리할 수 있는 치료법이 있습니다. 환자는 보통 두 가지 치료 단계를 거칩니다. 첫 번째는 증상 완화를 유도하는 치료(도입요법), 두 번째는 가능한 한 오랫동안 완치 상태를 유지하는 치료(유지요법)입니다.
시장 역학
시장의 주요 기업은 연구개발 활동에 집중하고 다양한 의학 컨퍼런스에서 연구 결과를 발표하는 데 중점을 두고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2022년 5월, 바이오 제약 기업 ChemoCentryx, Inc.는 세 개의 주요 의학 학회에서 발표할 예정이라고 발표했습니다. 이번 발표에서는 경구용 선택적 보체 5a 수용체(C5aR) 억제제 타브네오스(성분명: 아바코판)의 승인을 지원하는 주요 임상 3상 연구인 ADVOCATE의 결과와 ANCA 관련 혈관염에서 글루코코르티코이드 사용의 부담에 대한 연구가 다뤄질 예정입니다. 이 세 학회는 ATS 2022(미국 흉부학회, 2022년 5월 15일-17일, 샌프란시스코), ISPOR 2022(국제약물경제학 및 결과연구학회, 2022년 5월 15일-18일, 워싱턴), 제59회 ERA 학술대회(유럽신장학회, 2022년 5월 19일-22일) 일-22일, 프랑스 파리/온라인으로 개최됩니다.
본 조사의 주요 특징
- 이 보고서는 세계 ANCA 혈관염 치료제 시장에 대한 상세한 분석을 제공하며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모와 CAGR(%)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계의 ANCA 혈관염 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 ANCA 혈관염 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 ANCA 혈관염 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 ANCA 혈관염 치료제 시장 : 유형별, 2026-2033년
제5장 세계의 ANCA 관련 혈관염 치료제 시장 : 약제 유형별, 2026-2033년
제6장 세계의 ANCA 혈관염 치료제 시장 : 유통 채널별, 2026-2033년
제7장 세계의 ANCA 혈관염 치료제 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.04.30Anca Vasculitis Drug Market is estimated to be valued at USD 574.9 Mn in 2026 and is expected to reach USD 836.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 574.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.50% | 2033 Value Projection: | USD 836.3 Mn |
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).
Market Dynamics
Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual
Key features of the study
- This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market
Market Segmentation
- Global ANCA Vasculitis Drug Market, By Type
- Granulomatosis with Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Renal-limited Vasculitis
- Global ANCA Vasculitis Drug Market, By Drug Type
- Glucocorticoids
- Cyclophosphamide
- Rituximab
- Methotrexate
- Mycophenolate mofetil
- Azathioprine
- Mepolizumab
- Avacopan
- Others
- Global ANCA Vasculitis Drug Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global ANCA Vasculitis Drug Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- ChemoCentryx, Inc.
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Product Launch/Approvals
4. Global ANCA Vasculitis Drug Market, By Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Granulomatosis with Polyangiitis (GPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Microscopic Polyangiitis (MPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Renal-limited Vasculitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global ANCA Vasculitis Drug Market, By Drug Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Glucocorticoids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Cyclophosphamide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Rituximab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Methotrexate
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Mycophenolate mofetil
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Mepolizumab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Avacopan
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global ANCA Vasculitis Drug Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- ChemoCentryx, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vifor Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- InflaRx GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
